BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221207
DTEND;VALUE=DATE:20221209
DTSTAMP:20260516T024656
CREATED:20220727T082442Z
LAST-MODIFIED:20220727T082442Z
UID:34784-1670371200-1670543999@www.pharmajournalist.com
SUMMARY:3rd TIGIT Axis Therapies Summit
DESCRIPTION:In the context of a need to regroup and accelerate practice-changing cancer immunotherapies towards approval and to patients in need\, the 3rd TIGIT Axis Therapies Summit returns to reunite large pharma\, innovative biotechs and pioneering academics to discuss the full range of next-generation TIGIT axis targeted drug modalities and maximize TIGIT-axis targeting in the solid tumor\, blood cancer and non-oncology setting. \nCovering deciphering the mechanistic intricacies underlying TIGIT axis signaling\, defining combination partners that improve efficacy and strengthen TIGIT targeted pipelines\, exploring novel drug designs in terms of Fc functionality and IgG type\, identifying molecular signatures relevant to the tumor microenvironment and periphery to incorporating unique pharmacology properties into trial design\, this is your comprehensive guide for addressing the unique challenges of TIGIT axis targeted drug development and powering up your pipelines. \nThis year’s sharp two-day agenda leans into the clinical headwinds faced by so many immune checkpoint targets. As the space regroups\, join the conversation to build meaningful partnerships and maximize the clinical and commercial success of the next generation of TIGIT axis targeted drugs. \nFind out more here: https://ter.li/ir0syg
URL:https://www.pharmajournalist.com/event/3rd-tigit-axis-therapies-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221213
DTEND;VALUE=DATE:20221216
DTSTAMP:20260516T024656
CREATED:20220728T084521Z
LAST-MODIFIED:20220728T084521Z
UID:34801-1670889600-1671148799@www.pharmajournalist.com
SUMMARY:5th Annual RNA-Targeted Drug Discovery Summit
DESCRIPTION:RNA-Targeted Drug Discovery Summit returns for its fifth year this December. Join the summit for deep dive into new and emerging topics such as: \n\nInduced Proximity as a new class of “targeted RNA degraders”\nNext-generation probing and screening technologies to accelerate HIT identification and validation\nBiophysical\, biochemical\, and cell-based assay development strategies to identify and optimize small molecules interacting with RNA\nIn vivo pharmacology\, safety\, and efficacy early considerations to accelerate the transition from discovery to pre-clinical and clinical development\n\nView the event program here: https://ter.li/7qs017 \nSecure your place here: https://ter.li/jlh128 \nIf you have any further questions regarding the summit\, please contact us at info@hansonwade.com.
URL:https://www.pharmajournalist.com/event/5th-annual-rna-targeted-drug-discovery-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221213
DTEND;VALUE=DATE:20221216
DTSTAMP:20260516T024656
CREATED:20220822T112559Z
LAST-MODIFIED:20221018T100720Z
UID:34982-1670889600-1671148799@www.pharmajournalist.com
SUMMARY:2nd Synthetic Biology-Based Therapies Summit
DESCRIPTION:Returning for a second year the Synthetic Biology-Based Therapies Summit is the leading industry-defining forum made exclusively for leaders in the synthetic and engineered biology space\, focusing on the technical challenges that lie ahead in the path towards commercialization. \nDownload the event guide to find out more \nLearn from industry trailblazers at Arsenal Biosciences\, bit.bio\, Moderna\, MIT\, Novome Bio\, Strand Therapeutics\, Synlogic and more\, to support your efforts in developing safe and effective synthetic biology-based therapeutics. \nJoin Global Innovators to: \n\nLearn from the academics that are driving the future of synthetic biology development with the National Institute of Standards & Technology and Massachusetts Institute of Technology\nLeverage novel control strategies for improved therapeutic efficacy and patient safety with Arsenal Biosciences\, bit.bio\, CHAIN Biotechnology and Strand Therapeutics\nEmploy synthetic biology techniques in the clinic\, hearing about a variety of therapeutic applications with Kite Pharma: A Gilead Company\, Novome Biotechnologies and Senti Biosciences\nApply computation\, artificial intelligence\, and machine learning to engineered and synthetic biology with Lawrence Berkley National Laboratory and Sanofi\nExplore the potential for engineered biology as a tool for drug discovery and development with LifeMine Therapeutics and Merck & Co.
URL:https://www.pharmajournalist.com/event/2nd-synthetic-biology-based-therapies-summit/
LOCATION:(exact venue TBC)\, Boston\, US.
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221213
DTEND;VALUE=DATE:20221215
DTSTAMP:20260516T024656
CREATED:20220909T103058Z
LAST-MODIFIED:20220909T103058Z
UID:35114-1670889600-1671062399@www.pharmajournalist.com
SUMMARY:Advanced Wound Care Summit Europe 2022
DESCRIPTION:The Advanced Wound Care Summit EU is the first industry-led\, EU-focused\, forum on commercialising innovative wound care products. How will you comply with the EU MDR? What is the best strategy to ensure widespread clinical adoption and reimbursement? What can you do to engage with other wound care companies\, for collaboration or acquisition? Expect to hear from\, and network with\, wound care leaders\, across large wound care companies and SMEs. \nFind out how C-level Executives\, VPs and Directors of R&D are tackling the most pressing industry challenges\, seizing growth opportunities\, and building innovation. Whether an executive\, investor\, researcher or healthcare professional\, this meeting offers an empowering environment that allows you to secure your stake in the AWC market. \nTo know more visit: https://hubs.ly/Q01lR8NX0
URL:https://www.pharmajournalist.com/event/advanced-wound-care-summit-europe-2022/
LOCATION:TBC\, Berlin\, Germany
ORGANIZER;CN="Kisaco Research":MAILTO:Jodie.purser@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221214
DTEND;VALUE=DATE:20221215
DTSTAMP:20260516T024656
CREATED:20221018T101336Z
LAST-MODIFIED:20221018T105122Z
UID:35527-1670976000-1671062399@www.pharmajournalist.com
SUMMARY:PURIFY – Chromatography Purification Conclave
DESCRIPTION:PURIFY Conclaves are pioneers of dedicated conferences in India that will help stretch possibilities\, be it discovery\, development or scaleups! \nThe pharmaceutical industry continues to dwell deeper into the growing possibilities for chromatography purification; the PURIFY conclaves touches upon diverse aspects of chromatography purification. \nThe attendees at PURIFY get exposed to a myriad of topics that could change the way they work…change the way they purify. New separation techniques and approaches\, niche topics\, deeper understanding of preparative and process chromatography and allied fields\, and upcoming application areas that will provide quality substance to the discerning scientists. So\, if you wish to get that additional gram\, which is purer\, in as less a time\, with minimal resources…there will surely be something for you at PURIFY conclaves! \nThe annually occurring PURIFY Conclave is an initiative by Custage Marketing Solutions LLP\, a Mumbai based company. \nThe PURIFY conclave is attended by analytical and research chemists\, scientists with scale-up and process development knowledge\, managers\, group heads\, natural product purification experts\, experts from quality and manufacturing\, academicians\, policy makers\, supply chain heads etc. of this pharmaceutical – APIs\, peptides\, proteins\, oligonucleotides\, chiral molecules\, bio-pharmaceutical\, fine chemicals\, environmental studies\, food and beverage\, polymers\, biotechnology\, cosmetics and fragrance to understand the advancements in chromatography platforms. \nSo\, the purification expert in you will surely get answers to the daily challenges faced for you in your laboratories. And what’s more\, the knowledge comes to you from dignitaries who are institutions on their own in chromatography purification and related.
URL:https://www.pharmajournalist.com/event/purify-chromatography-purification-conclave/
LOCATION:Taj Skyline\, Ahmedabad
ORGANIZER;CN="Custage Marketing Solutions LLP":MAILTO:rashi@custage.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230110
DTEND;VALUE=DATE:20230113
DTSTAMP:20260516T024656
CREATED:20221007T084856Z
LAST-MODIFIED:20221007T084856Z
UID:35427-1673308800-1673567999@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes and Injectable Drug Devices Europe
DESCRIPTION:SAE Media Group’s 15th Annual Conference \nPre-Filled Syringes and Injectable Drug Devices Europe \nJanuary 10 – 12 2023 | London\, UK \nhttp://www.pre-filled-syringes.com/pharmajournalist \n————————————————————————- \nThe pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to increase patient centricity\, aid self-administration and deliver biologics that have large-volumes and novel formulations. This year’s conference will explore the exciting advances in the combination product drug delivery space and a future outlook exploring how pharma\, device developers and regulators can work together to encourage innovation. \n \nSAE Media Group’s 15th Annual Pre-Filled Syringes and Injectable Drug Devices Conference will be bigger than ever\, with a pre-conference focus day exploring the advances in PFS design for enhanced drug delivery proceeded by a two-day main conference comprising of morning keynote plenaries and parallel afternoon topic streams as detailed below: \n\nNovel Drug Products and Large Volume Delivery\nSustainability for Injectable Delivery Devices\nPrimary Packaging Development\nConnected Drug Delivery Devices\n\nTopics of discussion will include the latest updates in the combination product regulatory framework\, insights into the evolving digital health landscape for connected delivery devices\, considerations for the development of primary packaging\, utilising platform technology\, the delivery of novel drug formulations and large volume drug products\, patient centric approaches to device design as well as sustainable approaches for device development. \nThis event will not only bring you key insights you need to expand and enhance your injectable device portfolio but will also give you the opportunity to network with key players throughout the industry. \nBenefits of Attending: \n\nEngage with industry representatives on the latest trends within the pre-filled syringe and injectable device market\nHear about new technological advances in the delivery of large volume drugs\nExplore updates to drug device combination product design approaches considering patient preference at the forefront with case studies from big pharma representatives\nUnderstand the latest regulatory requirements from regulatory experts surrounding medical devices and digital health\nDelve into the considerations for material components for the development of primary packaging\nGain insight into how big pharma are incorporating sustainable approaches into drug device design\n\nWho should attend: \nAdvanz Pharma; AstraZeneca; Balda Medical GmbH & Co. KG; Bayer AG; Bayer Pharma; BD Medical; BD Medical – Pharmaceutical Systems; Becton Dickinson (BD); Boehringer Ingelheim; Boehringer Ingelheim GmbH & Co. KG; Boehringer Ingelheim Pharma GmbH & CO KG; Boehringer Ingelheim Pharma Gmbh & Co. Kg; BSI; BSI Group; Chiesi Ltd; Crux Product Design Ltd; DCA Design International; Device Development; Dr.Reddys; GlaxoSmithKline; GSK; Hoffmann-La Roche; Horizon Therapeutics GmbH; Ichnos Sciences; Janssen Pharmaceutical Companies; Johnson & Johnson; Johnson & Johnson (Janssen Pharmaceutical); Medincell; Merck Group; Midas Pharma Gmbh; Nemera; Novartis; Novo Nordisk; Novo Nordisk A/S; Owen Mumford; Pfizer; Pfizer UK; PharmaEssentia; Prescient Healthcare Group; RAUMEDIC AG; Sanofi; SCHOTT AG; SPM MEDICARE PVT LTD\, INDIA; Sustainable Healthcare Coalition; Takeda; Teva; Teva Pharmaceuticals; Teva Pharmaceuticals Industries Ltd.; Teva\, Combination Products; TUV Italia SRL; TUV SUD Japan Ltd.; TUV SUD Product Service GmbH; University of Liverpool; University of Southern Denmark; Zeon Europe GmbH; Zeon Specialty Materials ; \nSAE Media Group offer direct access to key decision makers through tailored sponsorship and exhibitor packages. \nFor details\, please contact Daniele Moreschi on: +44 (0)20 7827 6050 or dmoreschi@smi-online.co.uk \nFor all delegate enquiries\, contact Jamie Wilkinson on: +44 (0) 20 7827 6136 or jwilkinson@smi-online.co.uk \nAbout SAE Media Group Conferences: \nSAE Media Group Conferences connects global communities with focused networking conferences. We provide our customers with solutions through industry knowledge and collaboration that enables our attendees to return to their organisations better equipped to overcome their key business challenges. Our key events focus on Defence and Aerospace\, Pharmaceutical and Medical.  Each year we bring together over 5\,000 senior business professionals at our conferences. http://www.smgconferences.com \nSAE Media Group (SMG)\, a subsidiary of SAE International\, reports the latest technology breakthroughs and design innovations to a global audience of nearly 1\,000\,000 engineers\, researchers\, and business managers. SMG provides critical information these professionals need to develop new and improved products and services.
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-and-injectable-drug-devices-europe/
LOCATION:London\, UK
ORGANIZER;CN="SAE Media Group":MAILTO:RJones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230116
DTEND;VALUE=DATE:20230118
DTSTAMP:20260516T024656
CREATED:20220926T093554Z
LAST-MODIFIED:20220926T100546Z
UID:35289-1673827200-1673999999@www.pharmajournalist.com
SUMMARY:11th Annual Pharmaceutical Microbiology Conference
DESCRIPTION:11th Annual Pharmaceutical Microbiology Conference  \n16 – 17 January 2023 \nLondon\, UK\nhttp://www.pharma-microbiology.com/PJwl \n Sponsored by: Microgenetics  \nCo-chairs Di Morris\, Clinical Auditor\, AstraZeneca and Nigel Cryer\, Deputy Director Global Audit\, Sanofi  \nHarnessing Alternative Rapid Microbial Methods for a Successful Contamination Control Strategy  \n \nWe are delighted to announce SAE’s 11th Annual Pharmaceutical Microbiology Europe Conference taking place in London\, UK on the 16-17 January 2023. \nMicrobiology remains an essential tool for the detection of microorganisms present in biopharmaceutical and pharmaceutical batches. This conference will explore the most pressing topics in this thriving field\, from the movement toward process automation and increased regulatory stringency\, to the latest technologies in rapid microbiological testing methods and data integrity. \nEvent Hashtag: #MicrobiologyEurope \nKey Highlights for 2023 Conference: \n\nOptimise your contamination control strategy and review the initial impact of Annex 1\nLearn how to utilise the latest microbiological methods to modernise your contamination control strategy\nMaximise the data output from your environmental and microbial monitoring with proven strategies and technologies\nIncrease the diversity of your testing methodologies through industry case studies including the recombinant factor C assay and Monocyte Activation Test\n\nWho Should Attend? \nHeads of Microbiology\, Heads of Aseptic Processing\, Global Quality Directors\, Heads of GMP Compliance\, Quality & Compliance Heads\, Microbiology Senior Specialists\, Directors of Quality Control Biology\, Quality Control Managers\, Quality Assurance Managers\, Lean Managers\, Operations Managers\, Heads of Site Compliance\, Heads of Sterile Technology\, Global Microbiology Analytical Experts\, Cleanroom Managers\, Regulatory Affairs Managers\, Production Managers\, Quality Systems Managers \nDownload the brochure at: http://www.pharma-microbiology.com/PJwl
URL:https://www.pharmajournalist.com/event/11th-annual-pharmaceutical-microbiology-conference/
LOCATION:London\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230117
DTEND;VALUE=DATE:20230120
DTSTAMP:20260516T024656
CREATED:20221021T090337Z
LAST-MODIFIED:20221021T090337Z
UID:35537-1673913600-1674172799@www.pharmajournalist.com
SUMMARY:Spatial Biology for Immuno-Oncology Summit
DESCRIPTION:The inaugural Spatial Biology for Immuno-Oncology Summit runs at a crucial moment in time. Spurred on by technological advancement and successful case studies\, spatial technologies are set to become increasingly mainstream and accessible. If you’re not already\, now is the time to harness spatial technologies to power your immunotherapy research\, improve your clinical trials\, enhance your biomarker discovery\, and streamline your therapeutic development. \nUniting researchers\, technology providers\, and drug developers\, next January join your peers to hear the latest best-practice case studies on operationalizing technology\, integrating spatial into the clinic\, and developing a robust data analysis pipeline. This meeting will provide an unrivaled opportunity to solve your current spatial challenges to improve your ability to treat disease and identify drug targets in immuno-oncology. \nAcross 3 jam-packed days of content\, led by 20+ immuno-oncology leaders\, the Spatial Biology for Immuno-Oncology Summit is your only chance to discover how technologies that put omics and single-cell information in spatial context can improve your ability to treat disease and identify drug targets in immuno-oncology. \nJoin over 100 key industry stakeholders as they gather and leave no stone unturned to advance the application of this revolutionary technology. \nTo know more visit: https://bit.ly/3yYeUhw
URL:https://www.pharmajournalist.com/event/spatial-biology-for-immuno-oncology-summit/
LOCATION:The Westgate Hotel\, 1055 2nd Ave\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230123
DTEND;VALUE=DATE:20230125
DTSTAMP:20260516T024656
CREATED:20221007T091733Z
LAST-MODIFIED:20221007T091733Z
UID:35438-1674432000-1674604799@www.pharmajournalist.com
SUMMARY:Transdermal and Microneedle Drug Delivery
DESCRIPTION:SAE Media Group’s 2nd Annual Conference \nTransdermal and Microneedle Drug Delivery \nJanuary 23 – 24\, 2023 | London\, UK \nwww.transdermal-microneedle-delivery.co.uk/pharmajournalistel \n————————————————————————- \nSAE Media Group is proud to present the 2nd annual Transdermal and Microneedle Drug Delivery Conference\, taking place on the 23rd to 24th January 2023. \n \nThe 2023 Transdermal and Microneedle Drug Delivery Conference will explore real world applications of microneedles in drug delivery and strategies for advanced and user-centric device design. Regulation of transdermal delivery systems will be another key theme addressed\, in combination with clinical trial optimization. Engage in the latest innovations in device design\, development and formulation\, with case studies from expert key opinion leaders of this rapidly accelerating space. Other key areas will be microneedle vaccines and transdermal patches for management of chronic disease. \nThe two-day agenda offers you peer-to-peer networking with CEO’s\, Senior Vice presidents\, Directors\, Heads of Product Development and many more. \nBENEFITS OF ATTENDING: \n\nEngage with senior industry opinion leaders presenting their experiences and case studies in innovative device design and advanced drug product formulation\nGain insights from notified body and competent authority representatives addressing key regulatory requirements\nUnderstand how to optimize your lifecycle management strategy for a commercially successful device\nExplore and benchmark against industry advances in device design through case studies and real-world examples\n\nWHO SHOULD ATTEND: \n\nDrug-Delivery Device Developers\nMicroneedle Device Developers\nTransdermal Delivery Developers\nMicroarray Patch Developers\nMedical Device Engineers\nPrimary Packaging Material Designers\nSecondary Packagers\nSmart Device Developers\nTraining Device Developers\nDevice-Safety Solution Providers\nDrug Developers\nTransdermal Drug Product Developers\n\nEARLY-BIRD RATES:  \n\nBOOK BY 30TH SEPTEMBER AND SAVE £400\n\nRegistrations can be made on the event website at: www.transdermal-microneedle-delivery.co.uk/ \nTargeted Keywords \nTransdermal and Microneedle Drug Delivery\, transdermal\, drug development\, regulatory guidelines\, pharmaceutical industry\, drug delivery\, therapeutic sectors\, vaccines\, Parenteral administration\, combination products\, primary packaging\, sterile injectables\, connectivity\, human factors\, autoinjectors
URL:https://www.pharmajournalist.com/event/transdermal-and-microneedle-drug-delivery/
LOCATION:London\, UK
ORGANIZER;CN="SAE Media Group":MAILTO:RJones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230124
DTEND;VALUE=DATE:20230127
DTSTAMP:20260516T024656
CREATED:20220826T121137Z
LAST-MODIFIED:20220831T191624Z
UID:35017-1674518400-1674777599@www.pharmajournalist.com
SUMMARY:2nd Annual mRNA-Based Therapeutics Summit Europe
DESCRIPTION:The 2nd Annual mRNA-Based Therapeutics Summit Europe is the only end-to-end mRNA-dedicated meeting in Europe and the largest gathering for mRNA professionals outside of the United States. \nBuilt with biopharmaceutical industry insights\, this meeting will unite KOLs from Europe and the rest of the world to delve into the challenges associated with successfully designing and developing the next-generation of mRNA-based vaccines & therapeutics with improved specificity\, delivery & efficacy for immuno-oncology\, infectious diseases and beyond. \nHear from 35+ pioneering large pharma\, biotech\, and academic experts who are shaping the landscape of mRNA-based therapeutics and discover how they are addressing the major challenges facing the industry. \nWith more companies investing in their tools and technologies to innovate processes and technologies to address key challenges such as sequence optimization\, cell-specific payload expression\, and durability\, there has never been a more pivotal time to join European biopharma experts and discuss the following topics. \n-Emerging cell-enhancing or protein replacement therapies based on mRNA \n-Optimization of analytical and quality control protocols \n-Durability\, accessibility and immunogenicity challenges of mRNA therapeutics and vaccines \n-Enhancement of formulation\, process development and manufacturing processes \n-Need for clear regulatory path to support the technology whilst enabling speed to market \nTo learn more\, download your copy of the full event guide including all speakers and their session details: https://ter.li/tholw0
URL:https://www.pharmajournalist.com/event/2nd-annual-mrna-based-therapeutics-summit-europe/
LOCATION:TBC – Berlin\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:mailto:info@hansonwade.com?subject=2nd Annual mRNA-Based Therapeutics Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230124
DTEND;VALUE=DATE:20230127
DTSTAMP:20260516T024656
CREATED:20221011T104423Z
LAST-MODIFIED:20221208T115612Z
UID:35446-1674518400-1674777599@www.pharmajournalist.com
SUMMARY:DDR Inhibitors Summit 2023
DESCRIPTION:The 6th DDR Inhibitors Summit is taking place in-person for the first time in 3 years in Boston\, MA this January 24 – 26\, 2023. \nThe DNA damage response inhibitor space only continues to grow\, with progress being accelerated by a shift in focus onto next-generation targets like PolQ and WRN\, moving forward from monotherapies through combining targets and exploiting sensitivity caused by DDRis to enhance other therapies like radiotherapy. \nThe scope of this year’s meeting is to bring together leading minds in DDRi drug development to exploring these strategies and aim to address issues related to emerging DDR inhibitor resistance and maximizing efficacy\, as well as addressing the biggest challenge in the space right now\, toxicity. \nThe 3-day meeting will consist of a comprehensive overview of the DDR space\, with over 30+ world class speakers sharing insights preclinical updates\, progress in the clinic\, solutions to overcoming toxicity and improving patient selection. \nDon’t miss out on hearing from the best in the field on how to overcome toxicity and resistance during drug design as well as in the clinic\, to maximize efficacy and propel your DDR inhibitors to success. \nTo know more visit: https://ter.li/40qr50
URL:https://www.pharmajournalist.com/event/ddr-inhibitors-summit-2023/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230124
DTEND;VALUE=DATE:20230127
DTSTAMP:20260516T024656
CREATED:20221110T115619Z
LAST-MODIFIED:20221110T115619Z
UID:35763-1674518400-1674777599@www.pharmajournalist.com
SUMMARY:2nd HFpEF & HCM Drug Discovery & Development Summit
DESCRIPTION:The 2nd HFpEF & HCM Drug Discovery & Development Summit is the definitive industry forum dedicated to propelling drug discovery and development across emerging therapeutics including cell and gene therapies and the implementation of precision medicine. \n \nShake hands with industry pioneers prioritizing the development of therapeutic treatments to complement the new standard of care with SGLT2 inhibitors and understand how you can leverage advances in biomarkers for early detection of drug efficacy and clinical trial updates to inform your strategic decisions. \nJoin 80+ biopharma experts in research\, cardiovascular\, rare disease and precision medicine as they analyze the HFpEF patient population and translational drug development pathway to achieve new commercially viable and clinically accepted therapeutics. \nTo know more visit: https://bit.ly/3EjK5H3
URL:https://www.pharmajournalist.com/event/2nd-hfpef-hcm-drug-discovery-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230130
DTEND;VALUE=DATE:20230202
DTSTAMP:20260516T024656
CREATED:20221121T083953Z
LAST-MODIFIED:20221121T083953Z
UID:35900-1675036800-1675295999@www.pharmajournalist.com
SUMMARY:3rd TGF-β for Immuno-Oncology Drug Development Summit
DESCRIPTION:Exploit Understanding of TGF-β Biology\, Harness Clinically Validated Biomarkers & Advance Safe & Efficacious Clinical Programs for Maximal Therapeutics Benefit in Immuno-Oncology. \nIn the past year alone\, the field has learnt valuable lessons from the clinical trials and from the wider TGF-β field that will equip the immuno-oncology field with the knowledge needed to supercharge future TGF-β monotherapy or combinational therapeutics for precision medicine. \nFrom uncovering the effects and production of TGF-β in immune\, tumor and stromal cells to exploring predictive and pharmacodynamic TGF-β biomarkers for patient identification and assessing the clinical challenges that led to recent clinical failures\, the 3rd TGF-β for Immuno-Oncology Drug Development Summit is your one-stop-shop dedicated to harnessing you with the knowledge to unlock the potential of successfully targeting TGF-β. \nTailored with 18+ senior leaders\, the 2023 meeting will be taking place in-person for the first time – don’t miss your chance to be in the room for your comprehensive guide on TGF-β in immuno-oncology! \nWhether you are new to this field or a seasoned expert\, this meeting will provide you with the must-know takeaways from the basic biology to biomarkers to clinical trial design to overcome the clinical setbacks and produce a blockbuster TGF-β therapeutic. \nTo know more visit: https://ter.li/cjnpgy
URL:https://www.pharmajournalist.com/event/3rd-tgf-%ce%b2-for-immuno-oncology-drug-development-summit/
LOCATION:Marines Memorial Club and Hotel\, 609 Sutter St\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230202
DTEND;VALUE=DATE:20230203
DTSTAMP:20260516T024656
CREATED:20221208T120155Z
LAST-MODIFIED:20221208T120155Z
UID:36005-1675296000-1675382399@www.pharmajournalist.com
SUMMARY:Cancer Neoantigen Vaccines
DESCRIPTION:Over the last few decades\, immunotherapy has developed at a rapid rate in the treatment of cancer where neoantigens are the latest breakthrough in tumour immunotherapy. Today\, it is still unclear when a cancer vaccine will be made commercially available; what is the latest academic research showing us? What is the industry missing and where are we going? \nJoin us through a series of inspiring keynote presentations and engaging panel discussions to connect with top pioneers in the space\, to discuss the future of cancer immunotherapy and how neoantigens are transforming the field. \nUnlock the new era of vaccine development at Cancer Neoantigen Vaccines\, a 1-day digital conference taking place February 2\, 2023 and discover the path to commercial success with novel approaches toward cancer neoantigen vaccines. \nYou’ll shape the future of next generation cancer vaccine development with new oncolytic approaches and critical immunotherapy strategies and uncover\, key research on targets and evolution\, how to successfully enter global markets and the future of personalisation and beyond. \nYou can expect to uncover methods of identifying true targets and deep dive into the future of machine and deep learning in identifying neoantigens. Plus\, you’ll hear successful case studies and promising data on the latest neoantigen vaccine development and gain a deeper understanding of the future of vaccines in personalised medicine. Don’t miss your opportunity to be a part of the discussions with industry experts on their look to the future. \nAll of this plus much more without leaving your desk! Your digital pass gives you access to the full attendee list with video chat\, instant message\, and meeting request functionalities to connect with like-minded thought-leaders in the field to expand your network\, and access to the content on-demand for 10 working days post-event.
URL:https://www.pharmajournalist.com/event/cancer-neoantigen-vaccines/
LOCATION:Digital Conference
ORGANIZER;CN="Informa Connect":MAILTO:Danielle.horney@informa.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230208
DTEND;VALUE=DATE:20230210
DTSTAMP:20260516T024656
CREATED:20221025T104610Z
LAST-MODIFIED:20221025T104610Z
UID:35615-1675814400-1675987199@www.pharmajournalist.com
SUMMARY:14th Annual RNA Therapeutics Conference
DESCRIPTION:SAE Media Group invites you to join the 14th Annual RNA Therapeutics Conference\, taking place on 8 and 9 February 2023\, in London\, UK. \nBuilding on the success of previous years\, the RNA Therapeutics Conference will bring together industry experts from leading pharma and biotech companies to provide an expert and holistic view on the latest developments of the industry. \nRNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy\, personalised medicines\, and treatment of genetic\, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025\, growing at a CAGR of 7.5%. \nWith Covid-19 rapidly accelerating the RNA landscape through massive regulatory successes\, the recent advent of CRISPR\, an RNA-guided gene-editing technology\, as well as new strides in the delivery of messenger RNA transcribed in vitro\, there has been considerable progress in the development of RNA medicines and a major expansion of the RNA-therapeutics field. \nThis year’s conference will reflect on how the industry has adapted and played a pivotal role in global health over the past year and will discuss the takeaways for future mRNA therapeutic development. \nBenefits of attending: \n\nExplore how mRNA leads the way in the genetic medicine space as the next generation of novel drug modalities\nInvestigate the latest trends in AI drug discovery as a tool for designing novel RNA based therapeutics\nEnhance your knowledge of the latest innovations in RNA application and RNA delivery techniques with case studies from BioNTech\, Neuway Pharma and Ethris GmbH\nEngage in the growing advances and development of novel RNA molecules in the treatment of chronic respiratory\, neurodegenerative\, and infectious diseases\n\nWho should attend: \n\nDirectors of novel RNA therapies\nCEOs\nSenior and expert scientists\nChief Medical Officers\nChief Technical Officers\nSenior Vice Presidents\nGlobal Heads of mRNA R&D\nGlobal Medical Directors\nHeads of Translational Medicine\nDirector\, Clinical Pharmacology\nGlobal Head of RNA and Targeted Therapeutics\nClinical Science Director\nHead of Biology\nDirector\, Genetic Medicine\nAssociate Director\n\nEARLY-BIRD RATES: \n\nREGISTER BY 31ST OCTOBER AND SAVE £400\nREGISTER BY 3OTH NOVEMBER AND SAVE £200\nREGISTER BY 16TH DECEMBER AND SAVE £100
URL:https://www.pharmajournalist.com/event/14th-annual-rna-therapeutics-conference/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:lamprini.balasi@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230208
DTEND;VALUE=DATE:20230210
DTSTAMP:20260516T024656
CREATED:20221117T082926Z
LAST-MODIFIED:20221117T082926Z
UID:35834-1675814400-1675987199@www.pharmajournalist.com
SUMMARY:Healthcare Payment & Revenue Integrity Summit
DESCRIPTION:Introducing the only industry forum exclusively bringing together key decision-makers\, within health insurers and providers\, who are responsible for payment and revenue integrity\, value-based payment\, and networking relations. \nAt a time when both payers and providers are evaluating and streamlining internal payment and revenue integrity processes\, this networking conference has been established to breakdown silos\, by promoting discussion between clinical\, coding\, revenue cycle and payment departments to facilitate the development of efficient\, value-based healthcare systems. \nTo know more visit: https://healthcarepaymentrevenueintegritysummit.com
URL:https://www.pharmajournalist.com/event/healthcare-payment-revenue-integrity-summit/
LOCATION:ORLANDO\, FLORIDA
ORGANIZER;CN="Kisaco Research":MAILTO:marketing@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230208
DTEND;VALUE=DATE:20230210
DTSTAMP:20260516T024656
CREATED:20221128T102920Z
LAST-MODIFIED:20221128T103039Z
UID:35931-1675814400-1675987199@www.pharmajournalist.com
SUMMARY:6th Annual 3D Cell Culture Conference
DESCRIPTION:6th Annual 3D Cell Culture Conference \n8-9 February 2022 \nLondon\, UK\nhttp://www.3D-cellculture.com/PJwl \nSponsored: CelVivo\, Promega and Systemic Bio \nConference Co-chairs: \nPhillip Hewitt\, Global Head of Early Investigative Toxicology\, Merck \nRhiannon David\, Director\, Microphysiological Systems\, AstraZeneca  \nExploring the implementation of complex in-vitro models for drug development \nJoin us in February 2023\, as SAE Media Group’s 6th annual 3D Cell Culture Conference brings together industry experts from big pharma\, regulatory bodies\, and cutting-edge researchers to discuss the challenges and drivers of these medical technologies\, through case studies of the latest innovations in 3D Cell Culture models\, real world examples of clinical applications\, and insights into regulatory validation and high throughput screening to give a comprehensive look into this fast growing industry. \n3D Cell Culture has gained increasing momentum in the pharmaceutical industry over recent years\, with the global 3D Cell Culture market predicted to reach a value of $3.48 Billion by 2028. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery\, pathology modelling and validation\, safety and toxicity. 3D Cell Culture technology promises to offer increased translatability in models and reduce the costly rates of drug attrition in the discovery process — heralding the next major advance in the discovery of pharmaceuticals. \nEvent Hashtag: #3DCellCulture2023 \nKey Conference Highlights: \n\nDiscuss the uses of advanced cell technologies for human tissue bioengineering\nUncover the major benefits of 3D modelling in enhancing clinical translation and predictability\nUtilise 3D cell culture for personalised drug screening and high-throughput screening over traditional 2D methods\nLearn how to implement 3D Cell Culture techniques for antibody and cell and gene therapy discovery process\nDelve into advanced case studies looking into organ models: from the blood-brain barrier to liver spheroids\n\nWho Should Attend? \nBiotech / Pharma Companies – Investigative toxicologist\, Research Scientist\, Clinical Pharmacologist\, Cell Technologists\, Cell and Molecular Scientist\, Head of Translational Research\,  In-Vitro Toxicologists\,  Director of Drug Discovery\, Head of DMPK\, Chief Scientific Officer\,  R&D Scientist\, Head of R&D. \nAcademia – Cell Technology\, Stem Cell Sciences\, Biochemistry\, Protein Technology and Tissue Engineering \nSolution Providers – Manager\, Head of\, CEO\, Director\, Founder\, Account Manager\, President\, CSO\, Executive\, Managing Director\, Vice President\, COO\, Biomedical Engineers\, Head of External Collaboration \nOrganisations / Regulatory – Director\, Senior Science Advisor\, Scientific Officer\, Advisor for Toxicology
URL:https://www.pharmajournalist.com/event/6th-annual-3d-cell-culture-conference/
LOCATION:London\, UK
ORGANIZER;CN="SAE Media Group":MAILTO:simi.sapal@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230214
DTEND;VALUE=DATE:20230217
DTSTAMP:20260516T024656
CREATED:20221027T104008Z
LAST-MODIFIED:20221027T104008Z
UID:35627-1676332800-1676591999@www.pharmajournalist.com
SUMMARY:CRISPR AgBio Congress 2023
DESCRIPTION:The 5th Annual CRISPR AgBio Congress will unite research heads\, molecular biologists\, regulatory experts\, and product developers from large Ag companies\, innovative AgBiotechs\, academic groups and regulatory bodies to translate share the challenges and opportunities of translating cutting-edge CRISPR technology into a tangible product. If you are working to advance genome-edited crops or plants\, this is the must-attend meeting to network with the leading stakeholders progressing the space forward\, keep up with the latest technology advances & guidances\, and ensure your product is set up to help meet the significant food security challenges the world is currently facing. \nTo know more visit: https://ter.li/3nrx25
URL:https://www.pharmajournalist.com/event/crispr-agbio-congress-2023/
LOCATION:The Westin San Diego Bayview\, 400 W Broadway\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230221
DTEND;VALUE=DATE:20230224
DTSTAMP:20260516T024656
CREATED:20221027T104330Z
LAST-MODIFIED:20221027T104330Z
UID:35633-1676937600-1677196799@www.pharmajournalist.com
SUMMARY:Retinal Vascular Disease Drug Development Summit
DESCRIPTION:Retinal Vascular Disease Drug Development Summit is an event dedicated to creating a community space dedicated to overcoming the current challenges in drug development for retinal vascular diseases. \nThe management of these diseases has made remarkable advancements in previous years\, but the burden on patients remains high\, posing a need to develop novel therapeutics and delivery mechanisms that improve the efficacy and durability of anti-VEGF drugs and beyond. \nProviding you with an in-depth coverage of technical insights of anti-VEGF\, innovative non-VEGF targeting therapeutics for wet-AMD\, DME\, DR and RVO\, the Retinal Vascular Disease Drug Development Summit will address the specific challenges in utilizing preclinical models for retinal vascular disease\, understand key regulatory requirements\, and learn how to run effective clinical trials that utilize appropriate endpoints. \nJoin your colleagues from across R&D\, preclinical\, translational and clinical teams across the biopharmaceutical industry to streamline your drug development and address the significant and increasing unmet medical need. \nTo know more visit: https://ter.li/7xp7xc
URL:https://www.pharmajournalist.com/event/retinal-vascular-disease-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230221
DTEND;VALUE=DATE:20230223
DTSTAMP:20260516T024656
CREATED:20221102T085213Z
LAST-MODIFIED:20221102T085213Z
UID:35698-1676937600-1677110399@www.pharmajournalist.com
SUMMARY:6th CAR-TCR Summit Europe
DESCRIPTION: Join us in London this February to connect with those trailblazing the next wave of CAR and TCR based approaches from pre-clinical development with in vivo engineering and regulatory fast-track strategies to streamlined analytics and automation to make CAR and TCR therapies better\, and faster. \n \nTake advantage of cutting-edge innovation from global biopharma leaders in cell armouring\, combination approaches and multiplexing gene engineering to improve cell durability and trafficking across allogeneic and solid tumour indications\, and leave understanding the technical strategies to build automated\, closed-system manufacturing processes to ensure vein to vein time is less than a week. \nPromising data-driven case studies outlining next generation product design\, clinical trial set-up and manufacturing processes\, this meeting is your go-to to comprehensively assess the emerging improvements of CAR and TCR based therapies.  \nSee the full agenda here: https://ter.li/ulbn8o
URL:https://www.pharmajournalist.com/event/6th-car-tcr-summit-europe/
LOCATION:ExCeL London\, Royal Victoria Dock\, 1 Western Gateway\, London\, E16 1XL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230221
DTEND;VALUE=DATE:20230224
DTSTAMP:20260516T024656
CREATED:20221124T112536Z
LAST-MODIFIED:20221124T113110Z
UID:35914-1676937600-1677196799@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy for Muscular Disorders Summit
DESCRIPTION:The past twelve months have seen an unprecedented level of excitement\, investment\, and progression within the gene therapy for muscular disorders field. As the industry endeavours to move gene therapy treatment through the preclinical and clinical pipeline\, in context of reducing toxicity and increasing efficacy\, attending the 3rd Annual Gene Therapy for Muscular Disorders Summit has never been so crucial. \nThis year’s summit will return to Boston to reunite 100+ leading experts in biotech\, pharma and academia to continue to develop strategies to deliver safer and more effective gene therapies to muscle cells. \nThis summit will encompass all aspects of preclinical development and highlight the obstacles in clinical trials\, enabling you to address and overcome these challenges. \nTo know more visit: https://ter.li/wi2a51
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-for-muscular-disorders-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230221
DTEND;VALUE=DATE:20230224
DTSTAMP:20260516T024656
CREATED:20230202T105848Z
LAST-MODIFIED:20230202T105848Z
UID:36454-1676937600-1677196799@www.pharmajournalist.com
SUMMARY:11th Alzheimer’s & Parkinson’s DD Summit
DESCRIPTION:Welcome to the 11th Alzheimer’s & Parkinson’s Drug Development Summit \n \nWith a surge in preclinical investment\, fresh news of clinical pipeline progressions\, and a new era of therapies pending FDA approvals from Biogen\, Eisai\, and Denali Therapeutics\, 2022 has put neurodegenerative drug development back on the map. \nBuilding on the field’s momentum\, we are delighted to bring back the 11th Alzheimer’s & Parkinson’s Drug Development Summit\, dedicated to overcoming the translational challenges of targeting neurodegenerative mechanisms. This summit will unite neurodegenerative biopharma experts from discovery\, preclinical\, translational\, and clinical backgrounds to showcase the latest breakthroughs in Alzheimer’s\, Parkinson’s\, and related neurological disorders in 2022 and 2023 \nTo know more visit: https://ter.li/x0w74p
URL:https://www.pharmajournalist.com/event/11th-alzheimers-parkinsons-dd-summit/
LOCATION:Hyatt Centric Fisherman’s Wharf\, San Francisco\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:Info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230222
DTEND;VALUE=DATE:20230224
DTSTAMP:20260516T024656
CREATED:20221205T103427Z
LAST-MODIFIED:20221205T103427Z
UID:35996-1677024000-1677196799@www.pharmajournalist.com
SUMMARY:2nd Next Generation Kinase Inhibitors Summit
DESCRIPTION:Since Kinase inhibitors have proven to be efficacious and approvable targets\, fuelling recent investment into this exciting space as their therapeutic targeting is explored beyond oncology. However\, increasing resistance to existing programs and safety bottlenecks threaten further progress. The next wave of kinase targets depends on innovation. \nJoin the 2nd Next Generation Kinase Inhibitors Summit to connect with experts across discovery\, R&D\, and clinical medicine to discuss how to accelerate the next generation of kinase inhibitor drugs to market\, which displays maximal therapeutic efficacy and durable clinical responses. \nKey Topics: \n\nAssay Development\, Kinome Exploration & and Kinase-Focussed Drug Discovery Principles\nOvercoming Tumor Resistance\, Managing the Tumor Microenvironment\, and Improving Durability\nExploiting the RAS/MAPK Signalling Pathway\nMultikinase and Combination Therapies to Overcoming Resistance\nTargeting Established Pharmacological Mechanisms in Alternative Indications Beyond Oncology to Meet Unmet Needs\n\nDon’t miss this opportunity to join & network with 100+ Kinase Biology Experts under one roof\, hear from 18+ expert speakers from the space and showcase your work at the Scientific Poster Session. \nThis meeting is FREE for drug developers and researchers! \nTo know more visit: https://ter.li/sreltb
URL:https://www.pharmajournalist.com/event/2nd-next-generation-kinase-inhibitors-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230308
DTEND;VALUE=DATE:20230310
DTSTAMP:20260516T024656
CREATED:20221215T131203Z
LAST-MODIFIED:20221215T131251Z
UID:36101-1678233600-1678406399@www.pharmajournalist.com
SUMMARY:Targeted Intracellular Delivery Summit
DESCRIPTION:Achieve Therapeutic Localization with Selective\, Effective & Validated Delivery to Intracellular Targets \nOptimize Your Pipeline’s Therapeutic Index with Novel Delivery Systems to Overcome Endosomal Barriers in Target Cells \nSelective cell entry\, biological barriers and complexities in targeting chemistry have long restricted the ability of promising drug candidates to impactfully engage their intracellular sites of action without off-target toxicity implications. \nFast forward to 2023\, advances in nanomedicine technology\, the LNP enabled mRNA vaccine and emphasis on personalized medicine has triggered significant pipeline shifts towards complex nucleic-acid and biologic candidates. This clinical translation depends on novel delivery systems accessing previously elusive intracellular compartments. This is further evidenced by AstraZeneca\, Boehringer Ingelheim and Eli Lilly’s announcements of prioritized strategic investment in targeted intracellular delivery technologies. \nAt such a pivotal moment for the industry\, the Targeted Intracellular Delivery Summit arrives to bring Formulation\, Chemistry\, Delivery & Biology industry professionals to the forefront of cutting-edge science critical to accelerate pharmaceutical R&D. Join 80+ senior leaders to explore target identification\, tissue delivery\, engineering technologies\, endosomal escape\, delivery validation analytics and more. \nThis is your definitive meeting for unpresented data\, unrivalled insights and unmissable methodologies across the next-generation nano-platforms including LNPs\, EVs\, Liposomes & more\, creating new opportunities for the development of safer and efficacious oligonucleotide\, siRNA\, mRNA\, DNA delivery and protein payloads. \nUnleash the true potential of your pipeline by gaining the best picture of industry’s fast-paced nano-platform progress this March! \nTo know more visit: https://ter.li/i23a5q
URL:https://www.pharmajournalist.com/event/targeted-intracellular-delivery-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230313
DTEND;VALUE=DATE:20230315
DTSTAMP:20260516T024656
CREATED:20221213T115004Z
LAST-MODIFIED:20221213T115004Z
UID:36069-1678665600-1678838399@www.pharmajournalist.com
SUMMARY:SAE Media Group Proudly Presents the 4th Annual AI in Drug Discovery Conference
DESCRIPTION:SAE Media Group is proud to present its 4th Annual AI in Drug Discovery Conference\, taking place from 13 – 14 March 2023 in London\, UK. \nWith the recent pandemic highlighting the need for rapid drug discovery\, AI has become an area of increased interest. This is driven by the ability to discover drugs through the use of machine and deep learning. The current challenges within the drug discovery industry include the significant time consumption and expenses involved. This conference will discuss the solutions to these problems with presentations and updates from leading industry experts. \nAI in drug discovery is leading the way into a shorter\, cheaper and more successful R&D era where compound generation is automated\, drug synthesis is predictable and undruggable diseases are finally being targeted. \nThe uptake of structure-based target selection and innovative in-silico techniques are driving optimised\, more efficient drug discovery. This\, alongside sessions on automation\, robotics and how to improve patient-centricity in precision medicine are just some of the topics set to be discussed which you wouldn’t want to miss at the 4th annual AI in Drug Discovery Conference 2023. \nOur influential line-up of speakers will be taking to the stage from 13 – 14 March 2023 at the Copthorne Tara Hotel\, London to provide you with the latest insights and advice for you to take back to your business. \nKey Reasons to Attend: \n\nDELVE into key industry research focuses\, with talks on fragment-based selection\, in silico drug design and personalised medicine from GSK\, Bayer\, Janssen Pharmaceuticals and more\nINCREASE the diversity of your drug discovery programme with case studies in applying knowledge graphs\, molecular dynamic simulations\, and digital twins throughout the development process\nUTILISE breakthroughs in robotics\, automation and quantum chemical methods alongside AI to drive the next generation of drug discovery\nUNCOVER the role that international cooperation and open-source data played in the rapid development of Covid-19 treatments\, and how this can be an example for the future of pharmaceutical R&D\nLEARN how to implement AI and Machine Learning techniques throughout the discovery pipeline from antigens and genomics to proteins and peptides\n\nTo know more visit: www.ai-indrugdiscovery.com/PJ-EL
URL:https://www.pharmajournalist.com/event/4th-annual-ai-in-drug-discovery-conference/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:Hannah.blake@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230320
DTEND;VALUE=DATE:20230324
DTSTAMP:20260516T024656
CREATED:20221124T112949Z
LAST-MODIFIED:20221124T112949Z
UID:35918-1679270400-1679615999@www.pharmajournalist.com
SUMMARY:6th Annual Gene Therapy for Rare Disorders 2023 Summit
DESCRIPTION:As the gene therapy field continues to break records\, there are still significant challenges to overcome relating to safety\, efficacy\, and accessibility. The 6th Annual Gene Therapy for Rare Disorders 2023 Summit remains devoted to showcasing the top case studies and strategic learnings from the past year. With an expert speaking faculty devoted to bringing safer and more effective gene therapies to rare disease patients\, key questions will be answered on how best the field can overcome regulatory\, clinical\, manufacturing and pricing bottlenecks to progress gene therapies into and through the clinic. \n500+ leading experts from innovative biotechs\, large pharma\, academia and key service providers will be reuniting in Boston for 2023 to capitalize on recent success stories and collaborate over the most pressing industry challenges. An event vital to unlocking the full potential of your rare gene therapy program\, join us to keep your finger on the pulse and set up for success in 2023. \nTo know more visit: https://ter.li/bvmkei
URL:https://www.pharmajournalist.com/event/6th-annual-gene-therapy-for-rare-disorders-2023-summit/
LOCATION:Sheraton Boston Hotel\, 39 Dalton Street\, Boston\, MA\, 02199\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230328
DTEND;VALUE=DATE:20230330
DTSTAMP:20260516T024656
CREATED:20221213T120801Z
LAST-MODIFIED:20221213T120801Z
UID:36077-1679961600-1680134399@www.pharmajournalist.com
SUMMARY:Reuters Events: Pharma USA 2023
DESCRIPTION:Patient-first. Collaborative. Data and insights driven. Digitally underpinned. \nThese are the qualities of a healthcare system that actively serves its purpose – yet instead\, the US is hindered by mounting financial toxicity\, unprecedented politicization of science and eroding public trust. \nTo capitalize on three years of extraordinary momentum and lead healthcare’s reform\, pharma must embody the traits that healthcare needs to thrive and restructure in pursuit of change. \nSeize the moment at Reuters Events: Pharma USA 2023 to lead pharma’s internal revolution and drive this critical systemic transformation. Join North America’s visionary pharma changemakers\, leading solution providers\, patient experts and industry heavyweights to catapult commercial excellence\, ingrain patient-first strategies into the heart of pharma’s fabric and heed the long-awaited rebirth of America’s healthcare system. \nTo know more visit: https://bit.ly/3uJUp5O
URL:https://www.pharmajournalist.com/event/reuters-events-pharma-usa-2023/
LOCATION:Pennsylvania Convention Center\, 1101 Arch St\, Philadelphia\, PA\, 19107\, United States
ORGANIZER;CN="Reuters Events":MAILTO:Tahmeena.Miah@ThomsonReuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230328
DTEND;VALUE=DATE:20230331
DTSTAMP:20260516T024656
CREATED:20230310T091100Z
LAST-MODIFIED:20230310T091100Z
UID:36791-1679961600-1680220799@www.pharmajournalist.com
SUMMARY:8th Innate Killer Summit
DESCRIPTION:Dedicated to driving cost-effective\, efficacious\, safe\, durable\, scalable\, and globally accessible allogeneic\, cell-based\, and engager therapies\, the 8th Innate Killer Summit returns to cement your end-to-end education in innate immune therapeutics. Your industry-defining Innate Killer Summit brings crucial insights for everyone on your team\, with 4 content tracks spanning preclinical development\, clinical translation\, CMC\, process development\, and clinical scale manufacturing\, this is the definitive meeting to drive concept to commercial success of emerging innate immune therapies. \nDownload your copy of the Full Event Guide here. \nJoin over 250 experts from 120+ pioneering companies to drive novel gene engineering technologies\, gain regulatory know-how\, optimize lymphodepletion and cryopreservation\, and contrast cell sources for highly efficacious\, scalable off-the-shelf therapies. \nPromising brand-new speakers from new companies\, interactive discussion\, and engaging networking opportunities\, attend to forge new collaborations and realize the clinical potential of innate immune therapies. \nRegister your place here.
URL:https://www.pharmajournalist.com/event/8th-innate-killer-summit/
LOCATION:HILTON LA JOLLA TORREY PINES\, 10950 N. Torrey Pines Road\, La Jolla\, CA\, 92037\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230403
DTEND;VALUE=DATE:20230406
DTSTAMP:20260516T024656
CREATED:20230125T100124Z
LAST-MODIFIED:20230125T100331Z
UID:36350-1680480000-1680739199@www.pharmajournalist.com
SUMMARY:4th TCR-based Therapies for Solid Tumors Summit
DESCRIPTION:The first TCR-based therapy approval in the US and Europe at the start of last year sparked a rush of excitement\, investment and collaborations. As further developers move into the clinic and some near commercialization\, it’s time for this community to unite to address the critical bottlenecks faced in development\, from discovery to approval\, to guarantee smooth sailing through the clinic. \nThe 4th TCR-based Therapies for Solid Tumors Summit is returning to Boston as the must-attend forum for TCR experts to come together to share industry updates and next generation engineered approaches to boost therapy safety and efficacy. \nJoin leaders and newcomers including Immunocore\, Medigene\, Immatics\, Captain T Cell and Anocca as they collaborate to guarantee tumor-specificity\, prevent cross-reactivity\, boost TCR and target discovery\, enhance solid tumor durability and explore TCR modalities. \nHuge milestones were achieved for the TCR field in 2022\, however\, there’s no time to sit back and relax. Collaborate with like-minded TCR trailblazers to secure clinical validation and streamline the road from discovery to commercialization. \nTo know more visit: https://ter.li/h6mn96
URL:https://www.pharmajournalist.com/event/4th-tcr-based-therapies-for-solid-tumors-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230411
DTEND;VALUE=DATE:20230414
DTSTAMP:20260516T024656
CREATED:20230216T110911Z
LAST-MODIFIED:20230216T110911Z
UID:36612-1681171200-1681430399@www.pharmajournalist.com
SUMMARY:3rd Annual Ligase Targeting Drug Development Summit
DESCRIPTION:Hijacking E3 Ligases to Mediate Degradation & Modulation of Undrugged Targets \nAs a family of over 600 known proteins\, ligases pose immense potential as viable avenues for harnessing previously undrugged targets. Key challenges remain however to rapidly discover and identify novel and underexploited ubiquitin E3s. Furthermore\, bottlenecks exist in the development of the established ligases; Cereblon and VHL. \n \nIt is now critical that we harness Cryo-EM\, X-Ray crystallography\, and other visualization tools to fully understand the structure and function of these lesser-known E3s\, accelerate ligand screening with new and improved tools\, leverage advances in DMPK knowledge to address concerns over toxicity in Cereblon\, propel VHL from ‘academic’ to clinic\, and all in\, de-risk the translation of candidate ligases to the clinic. \nThe 3rd Ligase Targeting Drug Development Summit is returning with fresh understanding and data from the forerunners of the field and those who have recently joined the space. Together we will investigate ligase structural and functional biology\, screening tools for optimal ligase\, linker\, and ligand identification\, explore tissue specificity\, uncover the key modalities where ligases can succeed\, and showcase the novel assays that are maximizing validation to ensure success in the clinic. \nThis dedicated forum will provide an unrivaled meeting point for industry leaders all under one specialized forum to strategically accelerate and de-risk the process of identifying\, validating\, and therapeutically leveraging cell and tissue-specific ubiquitin E3 ligases for degradation or modulation of targets in oncology\, immunology\, and beyond. \nTo know more: https://ter.li/gapgsb
URL:https://www.pharmajournalist.com/event/3rd-annual-ligase-targeting-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR